<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363621</url>
  </required_header>
  <id_info>
    <org_study_id>ML29634</org_study_id>
    <nct_id>NCT02363621</nct_id>
  </id_info>
  <brief_title>Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME</brief_title>
  <official_title>Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arshad Khanani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sierra Eye Associates</source>
  <brief_summary>
    <textblock>
      This study is designed to compare the post injection inflammation and pain seen after
      intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME.

      The investigators will be evaluating patients (1-7 days) post injections for:

      1. Intraocular inflammation (defined as anterior chamber and/or vitreous cells 2. Pain (as
      measured on a standardized pain scale).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase II study of post injection pain and inflammation after
      intravitreally administered ranibizumab and aflibercept in 100 subjects with Diabetic Macular
      Edema. Treatment na√Øve and experienced patients will be enrolled. Treatment experienced
      patients with history of anti-vegf injections will be eligible as long as they have not
      received any intravitreal injection in the 3 months prior to the study visit. Patients will
      be randomized to receive either Lucentis 0.3 mg or Eylea 2.0 mg, and followed for a week. A
      non-injecting masked physician who is blinded to the treatment drug will evaluate the patient
      at baseline before the injection and then within 1-2 days and 5-7 days after the injection
      for anterior chamber and vitreous cells using slit lamp examination and indirect
      ophthalmoscopy. Pain will also be recorded at these visits using a standardized pain scale.

      Consented, enrolled subjects will receive open-label intravitreal injection of either 0.3 mg
      ranibizumab or 2.0 mg aflibercept. A standard intravitreal injection protocol will be
      followed. Patients will be revaluated at baseline, 1-2 days and 5-7 days post injections. A
      non-injecting physician will evaluate the patients for anterior chamber and vitreous
      inflammation; this physician will be blinded about the specific treatment. Anterior chamber
      inflammation is described as any cell or flare in the anterior chamber. These will be
      evaluated using Standardization of Uveitis Nomenculature (SUN) working group classifications.
      Pain score will be evaluated using a Numerical Rating Scale.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Intraocular Inflammation</measure>
    <time_frame>24 to 48 hours (visit #1)</time_frame>
    <description>Number of participants with intraocular inflammation as seen on slide lamp and dilated fundus exam.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Intraocular Inflammation</measure>
    <time_frame>5 to 7 days (visit #2)</time_frame>
    <description>Number of Participants With Intraocular Inflammation as seen on slit lamp and dilated fundus exam</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post Injection Pain Above 0 on a 11 Point Pain Scale.</measure>
    <time_frame>24 to 48 hours visit #1 and 5 to 7 days visit #2</time_frame>
    <description>Pain score rated on a 11 point numerical rating from 0-10 administered to each patient verbally at visit #1 and visit #2.
0 = no pain 10 = severe pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.3 Intravitreal injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of Ranibizumab 0.3 mg once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept 2.0 mg intravitreal injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Aflibercept 2.0 mg once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.3 mg</intervention_name>
    <description>Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg</description>
    <arm_group_label>Ranibizumab 0.3 Intravitreal injection</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept 2.0 mg</intervention_name>
    <description>Patient will receive intravitreal injection of Aflibercept 2.0 mg</description>
    <arm_group_label>Aflibercept 2.0 mg intravitreal injection</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be eligible if the following criteria are met:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 21 years

          -  Exam and OCT confirming Diabetic Macular Edema

          -  Visual Acuity of 20/400 or better

          -  No history of post injection pain or inflammation in the past

        Exclusion Criteria:

          -  Subjects who meet any of the following criteria will be excluded from this study

          -  History of Endophthalmitis in either eye

          -  Current inflammation in either eye

          -  Uncontrolled or symptomatic Dry Eye Syndrome

          -  Intravitreal injection less than 3 months ago

          -  History of Anterior or Posterior Uveitis

          -  History of post injection pain with prior treatments

          -  Recent thromboembolic event (&lt;3 months)

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using adequate contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arshad Khanani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sierra Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <results_first_submitted>November 4, 2018</results_first_submitted>
  <results_first_submitted_qc>April 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sierra Eye Associates</investigator_affiliation>
    <investigator_full_name>Arshad Khanani</investigator_full_name>
    <investigator_title>Vitreo-Retinal Diseases and Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 14, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02363621/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab 0.3 Intravitreal Injection</title>
          <description>Intravitreal injection of Ranibizumab 0.3 mg once
Ranibizumab 0.3 mg: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg</description>
        </group>
        <group group_id="P2">
          <title>Aflibercept 2.0 mg Intravitreal Injection</title>
          <description>Intravitreal Aflibercept 2.0 mg once
Aflibercept 2.0 mg: Patient will receive intravitreal injection of Aflibercept 2.0 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with diabetic macular edema</population>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab 0.3 Intravitreal Injection</title>
          <description>Intravitreal injection of Ranibizumab 0.3 mg once
Ranibizumab 0.3 mg: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg</description>
        </group>
        <group group_id="B2">
          <title>Aflibercept 2.0 mg Intravitreal Injection</title>
          <description>Intravitreal Aflibercept 2.0 mg once
Aflibercept 2.0 mg: Patient will receive intravitreal injection of Aflibercept 2.0 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic Macular Edema</title>
          <description>Diabetic Macular edema as seen on OCT and exam.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Intraocular Inflammation</title>
        <description>Number of participants with intraocular inflammation as seen on slide lamp and dilated fundus exam.</description>
        <time_frame>24 to 48 hours (visit #1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.3 Intravitreal Injection</title>
            <description>Intravitreal injection of Ranibizumab 0.3 mg once
Ranibizumab 0.3 mg: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept 2.0 mg Intravitreal Injection</title>
            <description>Intravitreal Aflibercept 2.0 mg once
Aflibercept 2.0 mg: Patient will receive intravitreal injection of Aflibercept 2.0 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Intraocular Inflammation</title>
          <description>Number of participants with intraocular inflammation as seen on slide lamp and dilated fundus exam.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Intraocular Inflammation</title>
        <description>Number of Participants With Intraocular Inflammation as seen on slit lamp and dilated fundus exam</description>
        <time_frame>5 to 7 days (visit #2)</time_frame>
        <population>Inflammation 5 to 7 days after injection</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.3 Intravitreal Injection</title>
            <description>Intravitreal injection of Ranibizumab 0.3 mg once
Ranibizumab 0.3 mg: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept 2.0 mg Intravitreal Injection</title>
            <description>Intravitreal Aflibercept 2.0 mg once
Aflibercept 2.0 mg: Patient will receive intravitreal injection of Aflibercept 2.0 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Intraocular Inflammation</title>
          <description>Number of Participants With Intraocular Inflammation as seen on slit lamp and dilated fundus exam</description>
          <population>Inflammation 5 to 7 days after injection</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post Injection Pain Above 0 on a 11 Point Pain Scale.</title>
        <description>Pain score rated on a 11 point numerical rating from 0-10 administered to each patient verbally at visit #1 and visit #2.
0 = no pain 10 = severe pain</description>
        <time_frame>24 to 48 hours visit #1 and 5 to 7 days visit #2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.3 Intravitreal Injection</title>
            <description>Intravitreal injection of Ranibizumab 0.3 mg once
Ranibizumab 0.3 mg: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept 2.0 mg Intravitreal Injection</title>
            <description>Intravitreal Aflibercept 2.0 mg once
Aflibercept 2.0 mg: Patient will receive intravitreal injection of Aflibercept 2.0 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post Injection Pain Above 0 on a 11 Point Pain Scale.</title>
          <description>Pain score rated on a 11 point numerical rating from 0-10 administered to each patient verbally at visit #1 and visit #2.
0 = no pain 10 = severe pain</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 to 48 hours visit #1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 to 7 days visit #2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab 0.3 Intravitreal Injection</title>
          <description>Intravitreal injection of Ranibizumab 0.3 mg once
Ranibizumab 0.3 mg: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg</description>
        </group>
        <group group_id="E2">
          <title>Aflibercept 2.0 mg Intravitreal Injection</title>
          <description>Intravitreal Aflibercept 2.0 mg once
Aflibercept 2.0 mg: Patient will receive intravitreal injection of Aflibercept 2.0 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>anterior chamber inflammation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Arshad Khanani</name_or_title>
      <organization>Sierra Eye Associates</organization>
      <phone>775-329-0286</phone>
      <email>Arshad.Khanani@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

